Amyotrophic Lateral Sclerosis

Unanswered questions in ALS research 1:44
Unanswered questions in ALS research
Clive Svendsen • 15 Mar 2022
Phase II and III studies of CNM-Au8 in ALS 1:32
Phase II and III studies of CNM-Au8 in ALS
Robert Glanzman • 13 Oct 2021
Gene-based therapies for neurodegenerative & neuromuscular diseases 3:23
Gene-based therapies for neurodegenerative & neuromuscular diseases
Aida Abu-Baker • 11 Oct 2021
How does C9orf72 expansion impact protein degradation pathways in FTLD and ALS? 4:02
How does C9orf72 expansion impact protein degradation pathways in FTLD and ALS?
Annakaisa Haapasalo • 16 Sep 2021
A novel genetic marker to detect C9orf72 repeat expansion carriers 3:43
A novel genetic marker to detect C9orf72 repeat expansion carriers
Annakaisa Haapasalo • 16 Sep 2021
Outcome measures in motor neuron diseases and neuropathies 3:03
Outcome measures in motor neuron diseases and neuropathies
Marianne de Visser • 28 Sep 2021
Novel outcome measures for ALS and SMA 3:26
Novel outcome measures for ALS and SMA
Marianne de Visser • 28 Sep 2021
Using antibodies and intrabodies to target pathogenic TDP-43 in ALS 6:05
Using antibodies and intrabodies to target pathogenic TDP-43 in ALS
Neil Cashman • 2 Aug 2021
MS research from EAN 2021 2:11
MS research from EAN 2021
Massimo Filippi • 17 Jun 2021
Collaboration between neurology and palliative care services in ALS 2:06
Collaboration between neurology and palliative care services in ALS
David Oliver • 11 Jun 2021
Palliative care improves QoL in advanced neurodegenerative disorders 4:46
Palliative care improves QoL in advanced neurodegenerative disorders
David Oliver • 11 Jun 2021
AMX0035 in ALS: long-term survival analysis of the CENTAUR trial 3:40
AMX0035 in ALS: long-term survival analysis of the CENTAUR trial
Sabrina Paganoni • 15 Apr 2021
A new era in the discovery of ALS treatments 0:56
A new era in the discovery of ALS treatments
Sabrina Paganoni • 15 Apr 2021
CNM-Au8 gold nanocatalysts to slow disease progression in ALS 3:11
CNM-Au8 gold nanocatalysts to slow disease progression in ALS
Robert Glanzman • 1 Mar 2021
The perpetual multi-center multi-regimen Healy-ALS Platform trial 0:46
The perpetual multi-center multi-regimen Healy-ALS Platform trial
Robert Glanzman • 1 Mar 2021
Debating controversies in ALS 2:54
Debating controversies in ALS
Ettore Beghi • 27 Oct 2020
The content of VJNeurology is intended for healthcare professionals